Novel oral agents for multiple sclerosis

被引：5

作者：

Burton, Jodie M. ^{[1
]}

O'Connor, Paul ^{[1
]}

机构：

[1] St Michaels Hosp, Div Neurol, Multiple Sclerosis Clin, Toronto, ON M5B 1W8, Canada

来源：

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2007年 / 7卷 / 03期

关键词：

D O I：

10.1007/s11910-007-0034-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In 1993, interferon beta-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trials have shown promise in efficacy and tolerability. This review assesses the results of the more thoroughly studied of these agents, some of which may soon be approved for use in multiple sclerosis.

引用

页码：223 / 230

页数：8

共 48 条

[31] Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study [J].

Schimrigk, S. ;

Brune, N. ;

Hellwig, K. ;

Lukas, C. ;

Bellenberg, B. ;

Rieks, M. ;

Hoffmann, V. ;

Poehlau, D. ;

Przuntek, H. .

EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (06) :604-610

[32] Lessons from linomide - A failed trial, but not a failure [J].

Schwid, SR ;

Trotter, JL .

NEUROLOGY, 2000, 54 (09) :1716-1717

[33] Statins as potential therapeutic agents in neuroinflammatory disorders [J].

Stüve, O ;

Youssef, S ;

Steinman, L ;

Zamvil, SS .

CURRENT OPINION IN NEUROLOGY, 2003, 16 (03) :393-401

[34] The potential therapeutic role of statins in central nervous system autoimmune disorders [J].

Stüve, O ;

Youssef, S ;

Dunn, S ;

Slavin, AJ ;

Steinmann, L ;

Zamvil, SS .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (11) :2483-2491

[35] Combination of IFNβ-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in multiple sclerosis [J].

Vermersch, P. ;

Waucquier, N. ;

Michelin, E. ;

Bourteel, H. ;

Stojkovic, T. ;

Ferriby, D. ;

de Seze, J. .

EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (01) :85-89

[36] Oral simvastatin treatment in relapsing-remitting multiple sclerosis [J].

Vollmer, T ;

Key, L ;

Durkalski, V ;

Tyor, W ;

Corboy, J ;

Markovic-Plese, S ;

Preiningerova, J ;

Rizzo, M ;

Singh, L .

LANCET, 2004, 363 (9421) :1607-1608

[37]

VOLLMER T, 2002, CONS MULT SCLER CTR

[38] A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis [J].

Walker, JE ;

Giri, SN ;

Margolin, SB .

MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (02) :149-158

[39] Pirfenidone for chronic progressive multiple sclerosis [J].

Walker, JE ;

Margolin, SB .

MULTIPLE SCLEROSIS JOURNAL, 2001, 7 (05) :305-312

[40] Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats [J].

Yang, HS ;

Xu, LY ;

Xiao, BG ;

Hedlund, G ;

Link, H .

JOURNAL OF NEUROIMMUNOLOGY, 2004, 156 (1-2) :3-9

← 1 2 3 4 5 →